An Act To Amend Title 16 Of The Delaware Code Relating To The Uniform Controlled Substances Act.
SB262 amends Delaware’s Uniform Controlled Substances Act to specifically address kratom and kratom-derived products. The bill defines “kratom” and “kratom product” broadly to include the plant Mitragyna speciosa, its active alkaloids such as mitragynine and 7-hydroxymitragynine, synthetic equivalents, and a wide range of consumer products containing those substances, including powders, capsules, beverages, gummies, and other edible or topical forms.
The bill places kratom, kratom products, and closely related synthetic analogues into Schedule I and adds quantity thresholds for kratom-related substances within Delaware’s drug offense tiers. It also creates a new section stating that individual possession of kratom, kratom products, or synthetic analogues may not be punished civilly or criminally, while manufacturing, selling, or delivering those products remains unlawful and subject to penalties. The bill further treats substances substantially similar to mitragynine or 7-hydroxymitragynine as controlled substance analogues.
The stated purpose is to fit kratom into the existing controlled substances framework rather than create a separate regulatory scheme. The substitute version described in the synopsis narrows the original approach by removing criminal penalties for simple possession, while preserving criminal liability for commercial activity and trafficking-related conduct. It also expands the definition of kratom products to capture items marketed under other names if they contain kratom’s active ingredients.
The overall sentiment in the available materials is cautionary and restrictive toward kratom, reflecting concerns about opioid-like effects, addiction potential, and overdose deaths cited in the synopsis. The bill’s framing suggests support for stronger state control over kratom distribution and synthetic analogues, while still avoiding punishment of individual users for mere possession. No committee debate or recorded votes are provided in the available context, so there is no direct evidence of opposition or support from legislators in the transcript record.
The main point of contention appears to be the balance between public health enforcement and personal possession. The substitute bill indicates an effort to avoid criminalizing individual users while targeting manufacturers, sellers, and distributors, which suggests the likely policy debate centered on whether kratom should be treated like a controlled substance, a regulated consumer product, or something in between. Another potential issue is the breadth of the definitions, especially the inclusion of synthetic analogues and products not labeled as kratom but containing its active compounds.
SB262 would amend Title 16 of the Delaware Code by adding kratom-specific definitions, placing kratom and related compounds into Schedule I, and integrating kratom quantities into Delaware’s existing drug offense tier system. It would also create a possession exemption for individuals while preserving criminal penalties for manufacturing, selling, delivering, and possession with intent to sell kratom products and synthetic analogues. The bill would therefore change how Delaware law classifies and prosecutes kratom-related conduct, affecting consumers, retailers, manufacturers, distributors, and law enforcement.
The bill’s tone is generally restrictive and public-safety oriented, with the synopsis emphasizing kratom’s opioid-like effects, addiction risk, and overdose associations. At the same time, the substitute version shows a more measured approach by removing penalties for simple possession, which suggests some concern about overcriminalization. Because there are no committee transcripts or votes in the provided record, the available materials do not show a documented legislative split, but the bill itself reflects an attempt to balance enforcement against commercial trafficking with leniency for individual possession.
The central controversy is whether kratom should be treated as a controlled substance and, if so, how broadly that control should extend. Supporters of the bill’s approach would likely focus on the alleged health risks, overdose data, and the need to stop unregulated sales of kratom products and synthetic analogues. Potential critics would likely object to Schedule I treatment, the breadth of the definitions, and the possibility that products containing kratom alkaloids could be swept in even when marketed under other names. The substitute’s removal of penalties for simple possession suggests that the most sensitive issue was criminalizing users versus targeting commercial actors.